Polatuzumab vedotin in relapsed / refractory aggressive B-cell lymphoma
Sign Up to like & getrecommendations! Published in 2022 at "Expert Review of Anticancer Therapy"
DOI: 10.1080/14737140.2022.2093191
Abstract: ABSTRACT Introduction Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive lymphoma histology. Outcomes for patients with relapsed or refractory (R/R) disease remain suboptimal. Polatuzumab vedotin (polatuzumab) is a recently approved antibody drug conjugate… read more here.
Keywords: cell lymphoma; relapsed refractory; vedotin relapsed; polatuzumab vedotin ... See more keywords
The molecular rationale for the combination of polatuzumab vedotin plus rituximab in diffuse large B‐cell lymphoma
Sign Up to like & getrecommendations! Published in 2022 at "British Journal of Haematology"
DOI: 10.1111/bjh.18341
Abstract: Polatuzumab vedotin (Pola) is an antibody–drug conjugate that targets the B‐cell antigen CD79b and delivers monomethyl auristatin E (MMAE). It is approved in combination with bendamustine and rituximab (Rit) for relapsed/refractory diffuse large B‐cell lymphoma… read more here.
Keywords: rationale combination; combination; rit; pola ... See more keywords
Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the Phase 3 POLARIX trial.
Sign Up to like & getrecommendations! Published in 2023 at "Blood"
DOI: 10.1182/blood.2022017734
Abstract: In the phase 3 POLARIX study (NCT03274492), polatuzumab vedotin combined with rituximab plus cyclophosphamide, doxorubicin and prednisone (Pola-R-CHP) significantly improved progression-free survival (PFS) compared with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with similar… read more here.
Keywords: chop; chp; pola chp; polatuzumab vedotin ... See more keywords
Randomized phase 2 trial of polatuzumab vedotin (pola) with bendamustine and rituximab (BR) in relapsed/refractory (r/r) FL and DLBCL.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.7507
Abstract: 7507Background: Pola is an antibody-drug conjugate targeting CD79b+ cells in B-NHL. Early results led to FDA breakthrough therapy status and EMA PRIME designation. We now report combined results fo... read more here.
Keywords: vedotin pola; randomized phase; pola bendamustine; trial polatuzumab ... See more keywords
A phase 3 study comparing polatuzumab vedotin plus R-CHP versus R-CHOP in patients with DLBCL (POLARIX).
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.tps7589
Abstract: TPS7589Background: R-CHOP remains the standard of care in patients (pts) with previously untreated diffuse large B-cell lymphoma (DLBCL). However, pts with high-risk disease have poorer outcomes wi... read more here.
Keywords: comparing polatuzumab; study comparing; vedotin plus; phase study ... See more keywords